This look at 4732 female BRCA carriers treated for breast cancer at age 40 or younger reveals 1 in 5…
Disease Categories
See MoreTop Line: First interim results of the CATNON trial demonstrated a big benefit with the…
Subscribe to Updates
Get the latest news from Quadshot.
Top Line: Can SABR dose be individualized for patients with lung tumors?The Study: In practice,…
The outcomes of the Chinese phase 3 NOTABLE trial that demonstrated across 92 patients with…
Top Line: Could concurrent immunotherapy improve the response rate for unresectable esophageal SCC treated with…
Almost any type of re-irradiation is (unfairly?) lumped in with a Hail Mary attempt with…
A large prospective analysis of 147 patients treated for esophageal squamous cell carcinoma in Hong…
Top Line:Immune checkpoint inhibition as consolidation for responders to definitive chemoradiation is the current standard…
The SINDAS trial established the safety and efficacy of combining radiation and EGFR-targeted therapy (erlotinib…